84 related articles for article (PubMed ID: 27855133)
1. Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool.
Saffian SM; Duffull SB; Roberts RL; Tait RC; Black L; Lund KA; Thomson AH; Wright DF
Ther Drug Monit; 2016 Dec; 38(6):677-683. PubMed ID: 27855133
[TBL] [Abstract][Full Text] [Related]
2. Methods for Predicting Warfarin Dose Requirements.
Saffian SM; Wright DF; Roberts RL; Duffull SB
Ther Drug Monit; 2015 Aug; 37(4):531-8. PubMed ID: 25549208
[TBL] [Abstract][Full Text] [Related]
3. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
Sasaki T; Tabuchi H; Higuchi S; Ieiri I
Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
[TBL] [Abstract][Full Text] [Related]
4. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
6. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
Cho SM; Lee KY; Choi JR; Lee KA
Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
8. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
[TBL] [Abstract][Full Text] [Related]
10. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
[TBL] [Abstract][Full Text] [Related]
11. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
12. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
13. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
14. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
15. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
16. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
18. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose].
Huang SW; Xiang DK; Wu HL; Chen BL; An BQ; Li GF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):661-5. PubMed ID: 22161100
[TBL] [Abstract][Full Text] [Related]
19. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 16 genotype-guided Warfarin Dosing Algorithms in 310 Korean Patients Receiving Warfarin Treatment: Poor Prediction Performance in VKORC1 1173C Carriers.
Yang M; Choi R; Kim JS; On YK; Bang OY; Cho HJ; Lee SY
Clin Ther; 2016 Dec; 38(12):2666-2674.e1. PubMed ID: 27887741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
